The current guidelines recommend initiation of anti-HBV therapy based on the natural course of chronic HBV infection, which consists of 4 phases: the immune-tolerance (IT), immune-clearance (IC), low-replicative (LR), and hepatitis B early antigen (HBeAg)-negative hepatitis (ENH) phases.3–5 Those phases are characterized by distinct patterns of serologic markers (HBeAg and hepatitis B surface antigen [HBsAg]), HBV DNA level, and level of serum alanine transaminase (ALT). The gene discussed is GPT; the disease is Hepatitis.